Summary

The global Duchenne muscular dystrophy (DMD) market is valued approximately at USD 1.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.7% over the forecast period 2024-2032. DMD is a genetic disorder marked by progressive muscle degeneration and weakness due to alterations in the dystrophin protein. Predominantly affecting males, the disease manifests in early childhood with symptoms such as delayed motor development and difficulties in learning to talk. The progressive nature of the disease leads to significant skeletal and cardiac muscle atrophy, necessitating comprehensive management strategies including glucocorticoid therapy and physical therapy to delay the onset of severe complications.
Current treatments focus on managing symptoms and improving quality of life. The development of exon skipping therapies, driven by significant advances in genetic research, has provided new avenues for market growth. The introduction of these therapies by key market players is expected to drive the market forward. Moreover, the increasing incidence of DMD and the active pipeline of novel drugs further bolster market expansion. However, the high cost associated with DMD treatments poses a significant barrier to market growth. Despite this, the rising demand for advanced healthcare services and the substantial investments in healthcare infrastructure, especially in emerging economies, present lucrative opportunities for market players. Governments' increased spending on the pharmaceutical and biotechnology sectors in developing countries is expected to further propel market growth.
The key region in the Global Duchenne Muscular Dystrophy Market include North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America accounted for the majority of the global market share in 2021 and is expected to maintain its dominance due to technological advancements and a robust hospital infrastructure. The Asia-Pacific region is projected to grow at the highest CAGR, fueled by rising DMD cases, healthcare infrastructure development, and increased investment in healthcare projects.


By Therapeutic Area
Molecular-Based Therapies
Steroid Therapy

By Distribution Channel
Hospital Pharmacies
Drug Store & Retail Pharmacies
Online Pharmacies

Key Market Players:
Hoffmann-La Roche AG
FibroGen, Inc
GlaxoSmithKline plc
Italfarmaco S.p.A.
Nippon Shinyaku Co., Ltd
Pfizer Inc.
PTC Therapeutics
Santhera Pharmaceuticals Inc
Sarepta Therapeutics
Wave Life Sciences Ltd.

By Region:
North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico
Rest of Latin America

Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global Duchenne Muscular Dystrophy Market Executive Summary
1.1. Global Duchenne Muscular Dystrophy Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Therapeutic Area
1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Duchenne Muscular Dystrophy Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Duchenne Muscular Dystrophy Market Dynamics
3.1. Market Drivers
3.1.1. Rising incidence of Duchenne muscular dystrophy
3.1.2. Advancements in genetic research and therapies
3.1.3. Increasing healthcare infrastructure investments
3.2. Market Challenges
3.2.1. High cost of treatments
3.3. Market Opportunities
3.3.1. Growing demand for advanced healthcare services
3.3.2. Government spending on pharmaceutical and biotechnology sectors
3.3.3. Development of innovative treatments

Chapter 4. Global Duchenne Muscular Dystrophy Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Therapeutic Area 2022-2032
5.1. Molecular-Based Therapies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2. Steroid Therapy Revenue Trend Analysis, 2022 & 2032 (USD Billion)

Chapter 6. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Distribution Channel 2022-2032
6.1. Hospital Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2. Drug Store & Retail Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.3. Online Pharmacies Revenue Trend Analysis, 2022 & 2032 (USD Billion)

Chapter 7. Global Duchenne Muscular Dystrophy Market Size & Forecasts by Region 2022-2032
7.1. North America Duchenne Muscular Dystrophy Market
7.1.1. U.S. Duchenne Muscular Dystrophy Market
7.1.1.1. Therapeutic Area breakdown size & forecasts, 2022-2032
7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
7.1.2. Canada Duchenne Muscular Dystrophy Market
7.2. Europe Duchenne Muscular Dystrophy Market
7.2.1. U.K. Duchenne Muscular Dystrophy Market
7.2.2. Germany Duchenne Muscular Dystrophy Market
7.2.3. France Duchenne Muscular Dystrophy Market
7.2.4. Spain Duchenne Muscular Dystrophy Market
7.2.5. Italy Duchenne Muscular Dystrophy Market
7.2.6. Rest of Europe Duchenne Muscular Dystrophy Market
7.3. Asia-Pacific Duchenne Muscular Dystrophy Market
7.3.1. China Duchenne Muscular Dystrophy Market
7.3.2. India Duchenne Muscular Dystrophy Market
7.3.3. Japan Duchenne Muscular Dystrophy Market
7.3.4. Australia Duchenne Muscular Dystrophy Market
7.3.5. South Korea Duchenne Muscular Dystrophy Market
7.3.6. Rest of Asia Pacific Duchenne Muscular Dystrophy Market
7.4. Latin America Duchenne Muscular Dystrophy Market
7.4.1. Brazil Duchenne Muscular Dystrophy Market
7.4.2. Mexico Duchenne Muscular Dystrophy Market
7.4.3. Rest of Latin America Duchenne Muscular Dystrophy Market
7.5. Middle East & Africa Duchenne Muscular Dystrophy Market
7.5.1. Saudi Arabia Duchenne Muscular Dystrophy Market
7.5.2. South Africa Duchenne Muscular Dystrophy Market
7.5.3. Rest of Middle East & Africa Duchenne Muscular Dystrophy Market

Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. F Hoffmann-La Roche AG
8.1.2. GlaxoSmithKline plc
8.1.3. Pfizer Inc.
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. FibroGen, Inc.
8.3.2. Italfarmaco S.p.A.
8.3.3. Nippon Shinyaku Co., Ltd
8.3.4. PTC Therapeutics
8.3.5. Santhera Pharmaceuticals Inc
8.3.6. Sarepta Therapeutics
8.3.7. Wave Life Sciences Ltd.

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes